A scientific and ethical fight has reignited over a U.S.-funded study of the hepatitis B vaccine in newborns in Guinea-Bissau, after a Danish university gave researchers approval this week to proceed with a revised version of the previously canceled trial.
The study, supported through the Centers for Disease Control and Prevention, is designed to examine whether the birth dose of the hepatitis B vaccine has unintended health effects. The vaccine has been used safely for decades, and when the trial first surfaced late last year, infectious-disease experts around the world denounced it as unethical — arguing that withholding a proven intervention from newborns violates the principles governing human research. The trial was canceled after an on-the-ground investigation raised major concerns about its protocol.
This week, the University of Southern Denmark said an independent ethical assessment had cleared the revised study to proceed, noting that an ethics panel in Guinea-Bissau had approved it and that national authorities there must still grant final authorization before any enrollment begins. Critics, including a U.S. science-advocacy organization, vowed to stop the study again, calling it a gross violation of human rights directed at some of the world’s most vulnerable people.
Inside the CDC, supporters of the trial had been waiting on the Danish review to revive the project, according to agency sources. For now, the study exists in a narrow space between an ethics approval in Copenhagen and an authorization decision in Bissau — with the health of newborns, and the standards of global research, at the center of the argument.
What the birth dose is designed to do
Hepatitis B is a virus that attacks the liver, and infection early in life carries a particularly high risk of becoming chronic. A dose given shortly after birth is intended to protect newborns who may be exposed during delivery, especially where a mother carries the virus without knowing it. Because newborn immune systems respond differently from those of older children and adults, timing has long been a central part of how health programs use this vaccine around the world.
In many countries, the birth dose sits alongside other newborn care, including screening of mothers where testing is available and follow-up doses in infancy that complete the series. The practical challenge in lower-resource settings is delivery: reaching facilities and homes quickly after birth, keeping vaccine at the right temperature and recording doses accurately. Research conducted in such settings therefore draws attention not only for its scientific question but also for how it interacts with systems that are already stretched.
Why trial design draws sustained scrutiny
Studies involving newborns receive close ethical review because participants cannot consent for themselves and because parents must decide under time pressure soon after delivery. Review typically considers whether the research question is important, whether existing evidence already answers it, whether any group would be denied care that is already standard, how risks and benefits are distributed and how parents will be informed. Independent ethics panels, university review and authorization by national authorities each address a different layer of that assessment.
A recurring concept in these debates is whether genuine uncertainty remains about the comparison being tested. Where a preventive measure is already widely used, reviewers examine especially carefully what participants in each study group would receive, what additional monitoring is offered and what safeguards exist if concerns emerge during the trial. Community engagement also matters, since trust built or lost during one study can affect participation in routine care long after the study ends.
What the current procedural moment means
The developments described in this case sit at the junction of those layers. A university clearance addresses institutional and scientific review. Approval by an ethics panel in the country where research would occur addresses local ethical assessment. Final authorization by national authorities is a separate, governmental step that must still occur before enrollment can begin. Each step on its own does not settle the wider disagreement, which is why advocates and critics can look at the same procedural update and reach opposing conclusions about what should happen next.
For readers following the dispute, the key distinction is between permission to consider a study further and permission to start it. The first keeps a proposal alive within a review system. The second allows researchers to approach families. In Guinea-Bissau, as in other countries that host internationally funded research, that distinction carries weight well beyond a single protocol, touching on sovereignty, standards of care and who decides what risks newborns should bear in the name of evidence.
Related reading: Updated Flu Shots Target the H3N2 'Super Flu' as Officials Urge October Vaccination · FDA Closes the Largest Cyclospora Outbreak on Record, Tied to Imported Iceberg Lettuce · FDA Flags Four Deaths in Evenamide Studies as U.S. Trial Hold Stays in Place
